Vivianne Nguyen, MD
Family Practice · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Bay Area Community Health · 106 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Nguyen’s office at (408) 729-9700 to ask if they take your plan before you enroll.
Medicaid work
$211,394 in 2024
Medicaid paid $211,394 for 2,170 billed services this clinician did in 2024, up to 171 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 726 | $201,373 |
| Short return visit (20+ min) | 1,275 | $8,831 |
| Short return visit | 125 | $736 |
| Return visit (30+ min) | 27 | $453 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 17 | $0 |
| 2024 | 2,170 | 5 | 171 | $211,394 |
| 2023 | 8,650 | 17 | 364 | $752,428 |
| 2022 | 10,604 | 25 | 353 | $853,502 |
| 2021 | 1,160 | 7 | 162 | $123,098 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 2,768 | $738,209 |
| Short return visit (20+ min) | 4,320 | $10,400 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years | 24 | $928 |
| Return visit (30+ min) | 384 | $788 |
| Hemoglobin A1C level | 129 | $560 |
| Short return visit | 250 | $421 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 16 | $375 |
| Blood glucose (sugar) level | 155 | $290 |
| Hemoglobin; by copper sulfate method, non-automated | 179 | $250 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 48 | $189 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 18 | $20 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 120 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 3,158 | $828,305 |
| Short return visit (20+ min) | 4,791 | $11,454 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 111 | $4,085 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years | 63 | $3,249 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 130 | $1,530 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 53 | $1,209 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 205 | $752 |
| Return visit (30+ min) | 325 | $737 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 22 | $544 |
| Hemoglobin; by copper sulfate method, non-automated | 219 | $359 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years | 15 | $347 |
| Hemoglobin A1C level | 56 | $265 |
2021
| Clinic visit/encounter, all-inclusive | 453 | $113,943 |
| Short return visit (20+ min) | 463 | $6,314 |
| Return visit (30+ min) | 138 | $2,664 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 22 | $106 |
| Hemoglobin; by copper sulfate method, non-automated | 59 | $71 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 13 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 12 | $0 |
Drugs they prescribed that Part D paid
$14,340
Pharmacies billed $14,340 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 242) in 2024. At or below the middle of the specialty; the typical family practice clinician is at 2%.
205 generic and 23 brand-name prescriptions · $14,340 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tamsulosin | 16 | $290 | $18 |
| Omeprazole | 18 | $224 | $12 |
| Rosuvastatin | 14 | $220 | $16 |
| Lisinopril | 16 | $114 | $7 |
| Famotidine | 11 | $99 | $9 |
See all 7 drugs
| Tamsulosin | 16 | $290 | $18 |
| Omeprazole | 18 | $224 | $12 |
| Rosuvastatin | 14 | $220 | $16 |
| Lisinopril | 16 | $114 | $7 |
| Famotidine | 11 | $99 | $9 |
| Atorvastatin | 15 | $98 | $7 |
| Metformin | 12 | $62 | $5 |
Year by year
| 2024 | 242 | 57 | 0% (0) | 10% | $14,340 |
| 2023 | 470 | 94 | 0% (0) | None | $47,541 |
| 2022 | 141 | 32 | 0% (0) | None | $10,452 |
| 2021 | 48 | 12 | 0% (0) | None | $796 |
| 2018 | 37 | 26 | None | None | $875 |
| 2017 | 116 | 81 | None | 16% | $2,244 |
| 2016 | 198 | 140 | None | None | $4,481 |
| 2015 | 95 | 64 | None | 16% | $2,913 |
| 2014 | 83 | 53 | None | 14% | $2,280 |
| 2013 | 21 | None | None | None | $1,640 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Atorvastatin | 43 | $743 | $17 |
| Amlodipine Besylate | 24 | $387 | $16 |
| Omega-3 Acid Ethyl Esters | 14 | $365 | $26 |
| Levothyroxine | 24 | $348 | $15 |
| Metformin | 26 | $333 | $13 |
| Simvastatin | 25 | $313 | $13 |
| Omeprazole | 13 | $275 | $21 |
| Losartan | 14 | $236 | $17 |
| Famotidine | 12 | $171 | $14 |
| Lisinopril | 18 | $148 | $8 |
| Hydrochlorothiazide | 15 | $145 | $10 |
| Metoprolol | 11 | $108 | $10 |
2022: 3 drugs
| Albuterol Sulfate Hfa | 11 | $487 | $44 |
| Atorvastatin | 12 | $115 | $10 |
| Lisinopril | 11 | $81 | $7 |
2017: 1 drug
| Doxycycline Hyclate | 14 | $319 | $23 |
2016: 6 drugs
| Doxycycline Hyclate | 17 | $688 | $40 |
| Nitrofurantoin Mono-Macro | 24 | $622 | $26 |
| Nystatin | 11 | $117 | $11 |
| Amoxicillin | 14 | $57 | $4 |
| Fluconazole | 12 | $54 | $4 |
| Sulfamethoxazole-Trimethoprim | 14 | $44 | $3 |
2015: 1 drug
| Doxycycline Hyclate | 12 | $533 | $44 |
Money from drug and device companies
$15 in 2025
| 2025 | 1 | 1 | None | $15 |
| 2023 | 1 | 2 | None | $35 |
| 2022 | 2 | 3 | None | $63 |
| 2021 | 1 | 1 | None | $116 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Hologic Sales and Service | Aptima | $15 | 1 payment
|
See the published payment
| Hologic Sales and Service | Meals · 2025-05-15 | Aptima | $15 |
See earlier years (2023, 2022, 2021)
2023: $35
| GlaxoSmithKline | Shingrix | $35 | 2 payments
|
2022: $63
| Gilead Sciences | None | $46 | 2 payments
|
| Novo Nordisk | Ozempic | $17 | 1 payment
|
2021: $116
| AbbVie | Mavyret | $116 | 1 payment
|
Professional record
- NPI
- 1528225802
- Licence
- MI 4301095529
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 5342 Dudley Blvd, Mcclellan, CA, 95652
- NPI first listed
- 2008-05-22
- NPI last updated
- 2011-12-16
This is when the NPI record was last certified, not a medical board exam.